Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +441494 818 026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
laura@zenopa.com
+441494 818 026

Testimonials
I would recommend Zenopa to any friends or colleagues who were contemplating a change in job/career. Throughout the recruitment process Zenopa have been contactable and have given me support.
Alex, 2014

Bristol-Myers Squibb reports trial data for new Orencia formulation

9 November 2010 00:00 in Pharmaceutical Company Product News


Bristol-Myers Squibb has published new clinical study data which illustrates the potential benefits of a new formulation of its drug Orencia.

The company has conducted a phase III trial to evaluate the efficacy of a weekly subcutaneous administration of the rheumatoid arthritis treatment, following a single intravenous (IV) loading dose.

It was found that the investigational formulation was able to deliver a similar improvement in disease activity to the currently approved monthly IV dosage method.

The results mean the therapy was able to meet its primary efficacy endpoint in the Acquire clinical study, which was conducted among 1,457 patients over six months.

Dr Mark Genovese, professor of medicine at Stanford University Medical Center, said: "These findings are significant because they demonstrate that subcutaneous Orencia may provide an additional administration option for patients and physicians."

Earlier this month, Bristol-Myers Squibb agreed a new collaboration with Simcere Pharmaceutical Group, a China-based company, to jointly develop a new cancer treatment.ADNFCR-8000103-ID-800224531-ADNFCR

Other news stories from 09/11/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd